Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

January 04, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005 Estimated average

0.5

OMB APPROVAL

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

response...

burden hours per

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Powchik Peter			2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner		
(Last) 777 OLD SAW	(First) (Middle) W MILL RIVER		3. Date of Earliest Transaction (Month/Day/Year) 01/02/2013	_X_ Officer (give title Other (specify below) SVP Clin Devel & Reg Affairs		
ROAD						
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
TARRYTOWN	J, NY 10591	1	Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		

(City)	(State)	(Zip) Tab	le I - Non-l	Derivative	Secur	ities Acqui	red, Disposed of,	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit onor Dispos (Instr. 3,	sed of 4 and 3	` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/02/2013		M(1)	30,000	A	\$ 21.25	44,990	D	
Common Stock	01/02/2013		F <u>(1)</u>	3,584	D	\$ 177.82	41,406	D	
Common Stock	01/02/2013		F(1)	12,830	D	\$ 177.82	28,576	D	
Common Stock	01/03/2013		S <u>(1)</u>	786	D	\$ 180.83	27,790	D	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock	01/03/2013	S <u>(1)</u>	6,200	D	\$ 181.51 (3)	21,590	D	
Common Stock	01/03/2013	S <u>(1)</u>	2,300	D	\$ 182.29 (4)	19,290	D	
Common Stock	01/03/2013	S(1)	4,300	D	\$ 183.1 (5)	14,990	D	
Common Stock						1,532	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	*		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Non-Qualified Stock Option (right to buy)	\$ 21.25	01/02/2013		M <u>(1)</u>	30,000	<u>(6)</u>	12/18/2019	Common Stock	30,0

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Powchik Peter 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591			SVP Clin Devel & Reg Affairs				

Signatures

By: Douglas McCorkle For: /s/**Peter 01/04/2013 Powchik

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 786 shares of Company stock on January 3, 2013 at prices ranging from \$180.44 to (2) \$180.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
- Represents volume-weighted average price of sales of 6,200 shares of Company stock on January 3, 2013 at prices ranging from \$181.00 (3) to \$181.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
- Represents volume-weighted average price of sales of 2,300 shares of Company stock on January 3, 2013 at prices ranging from \$182.03 (4) to \$182.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
- Represents volume-weighted average price of sales of 4,300 shares of Company stock on January 3, 2013 at prices ranging from \$183.01 (5) to \$180.3.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2013 at each separate price.
- (6) The option became exercisable with respect to all shares underlying the option on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012.
- (7) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3